| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 09/29/2005 | WO2005089800A1 PHARMACEUTICAL COMPOSITION CONTAINING hsHRD3 |
| 09/29/2005 | WO2005089799A1 Cytotoxicity method using effector function of anti-fam3d antibody |
| 09/29/2005 | WO2005089788A1 Medicine for cancer therapy |
| 09/29/2005 | WO2005089714A1 Emulsion stabilizer |
| 09/29/2005 | WO2005063801A3 Method for decreasing the contact between hepta-repeat region s of the corona-virus spike proteins and use thereof |
| 09/29/2005 | WO2005003335A9 Rapamycin resistant t cells and therapeutic uses thereof |
| 09/29/2005 | WO2004014314A3 Methods and compositions concerning poxviruses and cancer |
| 09/29/2005 | WO2003076469A9 Antibodies derived rom anti ed-b l19 and targeting tumor vasculature |
| 09/29/2005 | US20050216961 Cancer associated protein kinases and their uses |
| 09/29/2005 | US20050216958 Fucosyltransferase knock-out host cell for use as bioreactors in production of preferentially modified glycoproteins |
| 09/29/2005 | US20050215645 Naphthalene-1-(sulfonamide or carboxamide) derivatives; e.g. N-Benzyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide; protein kinase inhibitors sensitize cancer cells to radiotherapy or anticancer agents; side effect reduction |
| 09/29/2005 | US20050215642 Aromatic guanidine compound; antitumor agents; anticancer agents; for the treatment of breast cancer |
| 09/29/2005 | US20050215640 HMB compositions and uses thereof |
| 09/29/2005 | US20050215616 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol; treating vaginal and skin atrophy |
| 09/29/2005 | US20050215615 Medical compositions for intravesical treatment of bladder cancer |
| 09/29/2005 | US20050215613 with indazole or thienopyrazole compounds such as 3-(5'-hydroxymethyl-2'-furyl)-1-benzyl-indazole |
| 09/29/2005 | US20050215612 Anticancer agents; such as succinic acid mono-[5-(1-benzyl-1H-indazol-3-yl)-furan-2-ylmethyl]ester, sodium salt; inhibit cancer cell growth |
| 09/29/2005 | US20050215593 Kaposi's sarcoma; Crohn's disease |
| 09/29/2005 | US20050215579 consisting of lung, renal, prostate, uterine, melanoma and breast tumors; cyclodextrin inclusion compounds aid solubility |
| 09/29/2005 | US20050215574 4-anilino quinazoline derivatives as antiproliferative agents |
| 09/29/2005 | US20050215557 For therapy and prophylaxis of inflammatory diseases, asthma, atopic dermatitis, urticaria, allergic diseases, nephritis, nephropathy, hepatitis, arthritis or rheumatoid arthritis etc |
| 09/29/2005 | US20050215553 For therapy and prophylaxis of cardiovascular, central nervous system, inflammatory, and bone diseases as well as infectious diseases and certain cancers |
| 09/29/2005 | US20050215550 Pyrazole-derived kinase inhibitors and uses thereof |
| 09/29/2005 | US20050215549 TACE inhibitors |
| 09/29/2005 | US20050215547 Optically active pyridine derivative and a medicament containing the same |
| 09/29/2005 | US20050215534 Antiinflammatory agents; asthma; chronic obstructive pulmonary disease; dermatitis; antiallergens; antitumor agents; Aida; antiischemic agents; arrhythmia |
| 09/29/2005 | US20050215530 Combination therapy for the treatment of cancer |
| 09/29/2005 | US20050215528 Gnrh agonist combination drugs |
| 09/29/2005 | US20050215520 Complex of organic medicines and beta-cyclodextrin derivatives and its preparing process |
| 09/29/2005 | US20050215502 Regulation of endogenous gene expression in cells using zinc finger proteins |
| 09/29/2005 | US20050215500 aoaligonucleotides containing activated lymphocytes; antibody therapy; skin disorders; antiallergens |
| 09/29/2005 | US20050215497 Treating prostate cancer by administering double stranded oligonucleotide having two complementary oligonucleotide sequences forming a hybrid; each sequence has at one 3' or 5' end 1-5 unpaired nucleotides forming single-strand ends extending beyond the hybrid |
| 09/29/2005 | US20050215492 Ameliorant for chemical treament of cancer |
| 09/29/2005 | US20050215480 Alpha conotoxin peptides with analgesic properties |
| 09/29/2005 | US20050214903 O-superfamily conotoxin peptides |
| 09/29/2005 | US20050214795 Polypeptide for use as diagnostic indicator of cell proliferative disorders; immunotherapeutics; antitumor agents |
| 09/29/2005 | US20050214762 Receptor binding domains of leptin; proteolysis; fusion proteins |
| 09/29/2005 | US20050214394 Hippophae rhamnoides compositions for cancer therapy |
| 09/29/2005 | US20050214378 Stealth lipid nanocapsules, methods for the preparation thereof and use thereof as a carrier for active principle(s) |
| 09/29/2005 | US20050214375 Process for producing block copolymer/drug composite |
| 09/29/2005 | US20050214307 Antibody conjugates for treatment of neoplastic disease |
| 09/29/2005 | US20050214295 Combined chemotherapy compositions and methods for the treatment of cancer, ischemia-reperfusion injury, and septic shock |
| 09/29/2005 | US20050214272 Antiinflammatory agents for gastrointestinal inflammation involved with inflammatory bowel disease or irritable bowel syndrome |
| 09/29/2005 | US20050214262 Population of hematopoietic cells, made to exhibit a greater clonogenic potential, engraftment potential, immune system reconstitution potential and/or proportion of CD34+ positive cells by culturing with a transition metal compound that chelates copper such as tetraethylenepentamine |
| 09/29/2005 | US20050214249 Release nitric oxide under physiological conditions and are useful for treating biological disorders |
| 09/29/2005 | US20050214247 Glycodendrimers having biological activity |
| 09/29/2005 | CA2562388A1 Emulsion-stabilized preparation |
| 09/29/2005 | CA2560953A1 Therapeutic agent for auris interna disorder containing il-6 antagonist as active ingredient |
| 09/29/2005 | CA2560636A1 Glycosylation variants of ricin-like proteins |
| 09/29/2005 | CA2560305A1 Human anti-epidermal growth factor receptor antibody |
| 09/29/2005 | CA2560269A1 Combinatorial methods and compositions for treatment of melanoma |
| 09/29/2005 | CA2560059A1 Platinum carboxylate anticancer compounds |
| 09/29/2005 | CA2559919A1 Sulphonamide derivatives |
| 09/29/2005 | CA2559840A1 Prostatic acid phosphatase antigens |
| 09/29/2005 | CA2559545A1 Tetra-cyclic carboline derivatives for inhibiting angiogenesis |
| 09/29/2005 | CA2559408A1 Carboline derivatives useful in the inhibition of angiogenesis |
| 09/29/2005 | CA2559196A1 Novel dichloro-phenyl-pyrido [2,3-d] pyrimidine derivates, their manufacture and use as pharmaceutical agents |
| 09/29/2005 | CA2558020A1 Use of renin inhibitors in therapy |
| 09/29/2005 | CA2557836A1 Antisense composition and method for treating cancer |
| 09/29/2005 | CA2556915A1 Epothilone derivatives |
| 09/29/2005 | CA2554855A1 Derivatives of alkylpiperazine- and alkylhomopiperazine- carboxylates, preparation method thereof and use of same as faah enzyme inhibitors |
| 09/29/2005 | CA2554555A1 Oligosaccharides, preparation method and use thereof, and pharmaceutical compositions containing same |
| 09/29/2005 | CA2538289A1 Antibiotic fki-1778 and process for producing the same |
| 09/28/2005 | EP1580278A1 Process for producing macrolide compound |
| 09/28/2005 | EP1580216A1 High-molecular weight derivatives of camptothecins |
| 09/28/2005 | EP1580192A2 16-Hydroxyestratrienes as selective estrogens |
| 09/28/2005 | EP1580188A1 Aryl ureas as kinase inhibitors |
| 09/28/2005 | EP1580187A1 Apoptogenic and antiproliferative analogs of ceramide |
| 09/28/2005 | EP1579871A1 Vascular endothelial cell growth factor antagonists and uses thereof |
| 09/28/2005 | EP1579870A1 Vaccine comprising polynucleotide |
| 09/28/2005 | EP1579868A2 Use of IL-11 for treating various diseases |
| 09/28/2005 | EP1579857A1 Chemically stable compositions of 4-hydroxy tamoxifen |
| 09/28/2005 | EP1579213A1 Method of diagnosis,treatment and useful agents for conditions characterised by modulation in the level of activin beta c. |
| 09/28/2005 | EP1578996A2 Compositions and methods for the diagnosis and treatment of tumor |
| 09/28/2005 | EP1578988A2 Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders |
| 09/28/2005 | EP1578934A2 FLJ20647s AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE |
| 09/28/2005 | EP1578926A2 Novel prostate tumor-specific promoter |
| 09/28/2005 | EP1578924A2 Genomic screen for epigenetically silenced tumor suppressor genes |
| 09/28/2005 | EP1578914A2 Human ion channels |
| 09/28/2005 | EP1578912A2 Il-13 mutein proteins, antibodies, compositions, methods and uses |
| 09/28/2005 | EP1578902A2 Neurotransmission-associated proteins |
| 09/28/2005 | EP1578899A2 Secreted proteins |
| 09/28/2005 | EP1578897A2 Process for inducing functional tolerance to gene transfer products |
| 09/28/2005 | EP1578799A2 Antibodies directed to tumor necrosis factor and uses thereof |
| 09/28/2005 | EP1578797A1 The transmembrane protein amigo and uses thereof |
| 09/28/2005 | EP1578794A1 A novel phosphoprotein |
| 09/28/2005 | EP1578792A2 Novel centrosome-associated protein and applications thereof |
| 09/28/2005 | EP1578773A2 Methods and products based on oligomerization of stress proteins |
| 09/28/2005 | EP1578771A2 Remodeling and glycoconjugation of peptides |
| 09/28/2005 | EP1578760A2 Compositions and methods for the diagnosis and treatment of tumor |
| 09/28/2005 | EP1578758A2 Purine nucleosides |
| 09/28/2005 | EP1578751A1 Pyrrolopyrimidine derivatives |
| 09/28/2005 | EP1578736A1 Mek inhibiting oxa- and thia-diazol-2-yl-phenylamine derivatives |
| 09/28/2005 | EP1578724A2 Mitotic kinesin inhibitors |
| 09/28/2005 | EP1578721A2 Processes for the preparation of substituted isoxazoles and 2-isoxazolines |
| 09/28/2005 | EP1578711A2 Diterpenoid compounds, compositions thereof and their use as anti-cancer or anti-fungal agents |
| 09/28/2005 | EP1578480A2 Antagonists for human prolactin |
| 09/28/2005 | EP1578459A2 Apparatus and method for immunotherapy of a cancer through controlled cell lysis |
| 09/28/2005 | EP1578454A1 Ultrasound contrast using halogenated xanthenes |
| 09/28/2005 | EP1578451A2 Treating carcinoid neoplasms with therapeuthic viruses |